Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic plus systemic corticosteroids (combined therapy) showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids alone (low certainty).
2 findings from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes proportion of patients whose hearing is improved compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes final hearing threshold determined by PTA A lower value represents… compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Persistent tympanic membrane perforation · sudden sensorineural hearing loss
2 findings from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Ear pain: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care may leads to higher clinical improvement: discharged alive ( compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care showed no clear difference in clinical worsening: new need for invasive mechanical ventilation or… compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review